BioCryst (BCRX) Withdraws IND for BCX5191 Following Talks with U.S. FDA
Tweet Send to a Friend
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
